FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting

Mara Riminucci, Michael T. Collins, Neal S. Fedarko, Natasha Cherman, Alessandro Corsi, Kenneth White, Steven Waguespack, Anurag Gupta, Tamara Hannon, Michael Econs, Paolo Bianco, Pamela Gehron Robey

Research output: Contribution to journalArticle

Abstract

FGF-23, a novel member of the FGF family, is the product of the gene mutated in autosomal dominant hypophosphatemic rickets (ADHR). FGF-23 has been proposed as a circulating factor causing renal phosphate wasting not only in ADHR (as a result of inadequate degradation), but also in tumor-induced osteomalacia (as a result of excess synthesis by tumor cells). Renal phosphate wasting occurs in approximately 50% of patients with McCune-Albright syndrome (MAS) and fibrous dysplasia of bone (FD), which result from postzygotic mutations of the GNAS1 gene. We found that FGF-23 is produced by normal and FD osteoprogenitors and bone-forming cells in vivo and in vitro. In situ hybridization analysis of FGF-23 mRNA expression identified "fibrous" cells, osteogenic cells, and cells associated with microvascular walls as specific cellular sources of FGF-23 in FD. Serum levels of FGF-23 were increased in FD/MAS patients compared with normal age-matched controls and significantly higher in FD/MAS patients with renal phosphate wasting compared with those without, and correlated with disease burden bone turnover markers commonly used to assess disease activity. Production of FGF-23 by FD tissue may play an important role in the renal phosphate-wasting syndrome associated with FD/MAS.

Original languageEnglish
Pages (from-to)683-692
Number of pages10
JournalJournal of Clinical Investigation
Volume112
Issue number5
DOIs
StatePublished - Sep 2003

Fingerprint

Fibrous Dysplasia of Bone
Polyostotic Fibrous Dysplasia
Phosphates
Kidney
Wasting Syndrome
Bone and Bones
Bone Remodeling
Genes
In Situ Hybridization
Messenger RNA
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Riminucci, M., Collins, M. T., Fedarko, N. S., Cherman, N., Corsi, A., White, K., ... Robey, P. G. (2003). FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. Journal of Clinical Investigation, 112(5), 683-692. https://doi.org/10.1172/JCI200318399

FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. / Riminucci, Mara; Collins, Michael T.; Fedarko, Neal S.; Cherman, Natasha; Corsi, Alessandro; White, Kenneth; Waguespack, Steven; Gupta, Anurag; Hannon, Tamara; Econs, Michael; Bianco, Paolo; Robey, Pamela Gehron.

In: Journal of Clinical Investigation, Vol. 112, No. 5, 09.2003, p. 683-692.

Research output: Contribution to journalArticle

Riminucci, M, Collins, MT, Fedarko, NS, Cherman, N, Corsi, A, White, K, Waguespack, S, Gupta, A, Hannon, T, Econs, M, Bianco, P & Robey, PG 2003, 'FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting', Journal of Clinical Investigation, vol. 112, no. 5, pp. 683-692. https://doi.org/10.1172/JCI200318399
Riminucci, Mara ; Collins, Michael T. ; Fedarko, Neal S. ; Cherman, Natasha ; Corsi, Alessandro ; White, Kenneth ; Waguespack, Steven ; Gupta, Anurag ; Hannon, Tamara ; Econs, Michael ; Bianco, Paolo ; Robey, Pamela Gehron. / FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. In: Journal of Clinical Investigation. 2003 ; Vol. 112, No. 5. pp. 683-692.
@article{42afd6786a264c988dd7f299957818c1,
title = "FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting",
abstract = "FGF-23, a novel member of the FGF family, is the product of the gene mutated in autosomal dominant hypophosphatemic rickets (ADHR). FGF-23 has been proposed as a circulating factor causing renal phosphate wasting not only in ADHR (as a result of inadequate degradation), but also in tumor-induced osteomalacia (as a result of excess synthesis by tumor cells). Renal phosphate wasting occurs in approximately 50{\%} of patients with McCune-Albright syndrome (MAS) and fibrous dysplasia of bone (FD), which result from postzygotic mutations of the GNAS1 gene. We found that FGF-23 is produced by normal and FD osteoprogenitors and bone-forming cells in vivo and in vitro. In situ hybridization analysis of FGF-23 mRNA expression identified {"}fibrous{"} cells, osteogenic cells, and cells associated with microvascular walls as specific cellular sources of FGF-23 in FD. Serum levels of FGF-23 were increased in FD/MAS patients compared with normal age-matched controls and significantly higher in FD/MAS patients with renal phosphate wasting compared with those without, and correlated with disease burden bone turnover markers commonly used to assess disease activity. Production of FGF-23 by FD tissue may play an important role in the renal phosphate-wasting syndrome associated with FD/MAS.",
author = "Mara Riminucci and Collins, {Michael T.} and Fedarko, {Neal S.} and Natasha Cherman and Alessandro Corsi and Kenneth White and Steven Waguespack and Anurag Gupta and Tamara Hannon and Michael Econs and Paolo Bianco and Robey, {Pamela Gehron}",
year = "2003",
month = "9",
doi = "10.1172/JCI200318399",
language = "English",
volume = "112",
pages = "683--692",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting

AU - Riminucci, Mara

AU - Collins, Michael T.

AU - Fedarko, Neal S.

AU - Cherman, Natasha

AU - Corsi, Alessandro

AU - White, Kenneth

AU - Waguespack, Steven

AU - Gupta, Anurag

AU - Hannon, Tamara

AU - Econs, Michael

AU - Bianco, Paolo

AU - Robey, Pamela Gehron

PY - 2003/9

Y1 - 2003/9

N2 - FGF-23, a novel member of the FGF family, is the product of the gene mutated in autosomal dominant hypophosphatemic rickets (ADHR). FGF-23 has been proposed as a circulating factor causing renal phosphate wasting not only in ADHR (as a result of inadequate degradation), but also in tumor-induced osteomalacia (as a result of excess synthesis by tumor cells). Renal phosphate wasting occurs in approximately 50% of patients with McCune-Albright syndrome (MAS) and fibrous dysplasia of bone (FD), which result from postzygotic mutations of the GNAS1 gene. We found that FGF-23 is produced by normal and FD osteoprogenitors and bone-forming cells in vivo and in vitro. In situ hybridization analysis of FGF-23 mRNA expression identified "fibrous" cells, osteogenic cells, and cells associated with microvascular walls as specific cellular sources of FGF-23 in FD. Serum levels of FGF-23 were increased in FD/MAS patients compared with normal age-matched controls and significantly higher in FD/MAS patients with renal phosphate wasting compared with those without, and correlated with disease burden bone turnover markers commonly used to assess disease activity. Production of FGF-23 by FD tissue may play an important role in the renal phosphate-wasting syndrome associated with FD/MAS.

AB - FGF-23, a novel member of the FGF family, is the product of the gene mutated in autosomal dominant hypophosphatemic rickets (ADHR). FGF-23 has been proposed as a circulating factor causing renal phosphate wasting not only in ADHR (as a result of inadequate degradation), but also in tumor-induced osteomalacia (as a result of excess synthesis by tumor cells). Renal phosphate wasting occurs in approximately 50% of patients with McCune-Albright syndrome (MAS) and fibrous dysplasia of bone (FD), which result from postzygotic mutations of the GNAS1 gene. We found that FGF-23 is produced by normal and FD osteoprogenitors and bone-forming cells in vivo and in vitro. In situ hybridization analysis of FGF-23 mRNA expression identified "fibrous" cells, osteogenic cells, and cells associated with microvascular walls as specific cellular sources of FGF-23 in FD. Serum levels of FGF-23 were increased in FD/MAS patients compared with normal age-matched controls and significantly higher in FD/MAS patients with renal phosphate wasting compared with those without, and correlated with disease burden bone turnover markers commonly used to assess disease activity. Production of FGF-23 by FD tissue may play an important role in the renal phosphate-wasting syndrome associated with FD/MAS.

UR - http://www.scopus.com/inward/record.url?scp=0141835045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141835045&partnerID=8YFLogxK

U2 - 10.1172/JCI200318399

DO - 10.1172/JCI200318399

M3 - Article

VL - 112

SP - 683

EP - 692

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -